Interruption of apixaban doesn't impact bleeding in A-fib

December 21, 2017

(HealthDay)—For patients undergoing catheter ablation for nonvalvular atrial fibrillation (AF), both uninterrupted and minimally interrupted apixaban are associated with a very low rate of thromboembolic events, according to a study published online Dec. 20 in JACC: Clinical Electrophysiology.

Matthew R. Reynolds, M.D., from Lahey Hospital & Medical Center in Burlington, Mass., and colleagues randomized 300 patients undergoing for nonvalvular AF to uninterrupted or minimally interrupted peri-procedural apixaban. For comparison, a retrospective cohort of patients treated with uninterrupted warfarin at the same centers was matched to the apixaban-treated subjects.

The researchers identified no stroke/systemic embolism events. Overall, 11.3 percent of the 150 evaluable patients on uninterrupted apixaban and 9.7 percent of 145 evaluable patients on interrupted apixaban had clinically significant bleeding (risk difference, 1.7 percent; 95 percent confidence interval, −5.5 to 8.8 percent; P = NS). The rates of major bleeding were 1.3 and 2.1 percent in the uninterrupted apixaban and interrupted apixaban groups, respectively (risk difference, −0.7 percent; P = NS). For all apixaban combined, the rates of clinically significant and were similar (10.5 and 1.7 percent, respectively) to those of the matched warfarin group (9.8 and 1.4 percent, respectively).

"Both uninterrupted and minimally interrupted at the time of AF were associated with a very low rate of thromboembolic events, and rates of both major (<2 percent) and clinically significant bleeding, which were similar to uninterrupted warfarin," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Explore further: Apixaban lowers stroke risk in atrial fibrillation patients undergoing cardioversion

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Apixaban lowers stroke risk in atrial fibrillation patients undergoing cardioversion

August 28, 2017
Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented ...

Lower risk of gastrointestinal bleeding for apixaban

April 10, 2017
(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Apixaban Tx cost in A-fib meets U.S. norms for reasonable value

March 31, 2017
(HealthDay)—Apixaban therapy is cost-effective for atrial fibrillation from the perspective of the U.S. health care system, according to a study published online March 29 in JAMA Cardiology.

ISTH: Apixaban non-inferior to conventional treatment for VTE

July 1, 2013
(HealthDay)—For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according ...

Apixaban superior to warfarin for preventing stroke, reducing bleeding and saving lives

August 28, 2011
A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in ...

How safe and effective are new drugs for stroke prevention?

October 3, 2016
For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect ...

Recommended for you

A better clot-buster drug for strokes?

April 26, 2018
(HealthDay)—After a stroke, many patients are given the clot-busting intravenous drug alteplase, but another drug may be more effective, Australian researchers report.

Imaging may allow safe tPA treatment of patients with unwitnessed strokes

April 25, 2018
A study led by Massachusetts General Hospital (MGH) investigators may lead to a significant expansion in the number of stroke patients who can safely be treated with intravenous tPA (tissue plasminogen activator), the "clot ...

Mice make over four times as many new heart muscle cells when they exercise, study finds

April 25, 2018
Doctors, health organizations, and the Surgeon General all agree that exercise is good for the heart—but the reasons why are still not well understood.

Heart disease may only be a matter of time for those with healthy obesity

April 24, 2018
People who are 30 pounds or more overweight may want to slim down a bit even if they don't have high blood pressure or any other heart disease risk, according to scientists at Wake Forest Baptist Medical Center.

Women at greater risk of stress-induced ischemia after heart attacks

April 24, 2018
Women who've previously experienced a heart attack have twice the risk of later myocardial ischemia provoked by mental stress when compared to men with a similar history, according to a study published in Circulation.

A wearable device intervention to increase exercise in peripheral artery disease

April 24, 2018
A home-based exercise program, consisting of wearable devices and telephone coaching, did not improve walking ability for patients with peripheral artery disease, according to a new Northwestern Medicine study.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.